Translational Science ReviewBrolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration
Abbreviations and Acronyms
Cited by (0)
The goal is to provide authoritative and cutting-edge reviews of topical state-of-the-art basic research that is expected to have broad clinical impact in the next few years. This is primarily a “by invitation only” submission type; however, if you have suggestions for topics, please contact Marco Zarbin, MD, PhD ([email protected]), the editor for this section.
Financial Disclosure(s): The author(s) have made the following disclosure(s): Q.D.N.: Grants – Novartis, Genentech, Regeneron, Aerie.
D.V.D.: Consultant – Genentech, Regeneron, Santen, Novartis, Kodiak Sciences.
P.D.: Consultant – Acucela, Aerie Pharmaceutical, Aerpio, Alcon, Alimera Sciences, Allergan, Amgen, Annidis, ArcticDx, Bausch + Lomb Pharma, Boehringer Ingelheim, ByeOnics, Chengdu Kanghong Biotechnology, Clearside Biomedical, DigiSight Technologies, DOSE Medical, Genentech, Graybug Vision, Irenix, Kodiak Sciences, Lutronic, Lux BioSciences, MacuSight, NeoVista, Neurotech, Novartis, Oculis SA, Omeros, Ophthotech, Ophthea, Optovue, ORA, PanOptica, Pentavision, pSivida Corporation, Roche, Santen, SciFluor Life Sciences, Shire Human Genetic Therapies, Spark Therapeutics, Stealth Bio Therapeutics, Thrombogenics, TopCon, Zeiss Group; Minor stock shareholder – Alimera Sciences, Aerpio Therapeutics, Annidis, ArcticDx, Clearside Biomedical, DigiSight Technologies, Irenix, Ophthotech, PanOptica.
A.G.: Consultant – Alcon, Bayer, Novartis, Allergan, Dorc (Dutch Ophthalmics).
F.G.H.: Grants and personal fees – Alcon/Novartis, during the conduct of the study; Consultancy – Heidelberg Engineering, Zeiss, Acucela, Genentech/Roche, Allergan, Boehringer-Ingelheim, Bayer Healthcare, LIN Bioscience, Pixium, Kodiak; Grants/grants pending paid to his institution – Nightstar, Optos, Heidelberg Engineering, Carl Zeiss Meditec, Allergan, Roche/Genentech, Pixium, and Bayer; Payment for lectures/speakers bureaus – Roche/Genentech, Zeiss, Heidelberg Engineering, Bayer Healthcare, outside the submitted work.
N.P.: Employee – Novartis Pharmaceuticals (New Jersey).
H.M.: Former employee – Novartis Institutes for Biomedical Research (Massachusetts).
P.M.: Employee – Novartis Institutes for Biomedical Research (Basel, Switzerland).
Editorial support was provided by Imprint Science and funded by Novartis Pharmaceuticals.
HUMAN SUBJECTS: No human subjects, human-derived materials, or human medical records were part of this study protocol. The requirement for informed consent was waived because of the retrospective nature of the study.
No animal subjects were used in this study.
Author Contributions:
Conception and design: Nguyen, Das, Do, Dugel, Gomes, Holz, Koh, Pan, Sepah, Patel, MacLeod, Maurer
Data collection: Nguyen, Das, Do, Dugel, Gomes, Holz, Koh, Pan, Sepah, Patel, MacLeod, Maurer
Analysis and interpretation: Nguyen, Das, Do, Dugel, Gomes, Holz, Koh, Pan, Sepah, Patel, MacLeod, Maurer
Obtained funding: Nguyen, Do, Dugel, Gomes, Holz, Pan
Overall responsibility: Nguyen, Das, Do, Dugel, Gomes, Holz, Koh, Pan, Sepah, Patel, MacLeod, Maurer